Let’s reconsider your research – InnoSer contract breeding services

Let’s reconsider your research – InnoSer contract breeding services

COVID-19 restrictions brought extra challenges to breeding and maintaining colonies within academic facilities. If you are looking for a service provider resilient to today’s vulnerable environment, InnoSer is here to support you. Let’s put your research back on track...
InnoSer participates in the AACR annual meeting 2020

InnoSer participates in the AACR annual meeting 2020

InnoSer is proud to announce its participation in the annual meeting of the American Association for Cancer Research. As committed contributors to the preclinical oncology field, we look forward to interacting with the community throughout the event. We make this...
InnoSer joins the Eurostars funded project ‘LEMONAID’

InnoSer joins the Eurostars funded project ‘LEMONAID’

LEMONAID takes on the challenge of developing a new drug against Diffuse Large B-Cell Lymphoma (DLBCL) tumors to ultimately reduce drug resistance and relapse potential for patients. InnoSer supports this ambition by its expertise in combined in-vitro and in-vivo...
InnoSer meets you at knowledge for growth event

InnoSer meets you at knowledge for growth event

Organized by flanders.bio since it’s establishment in 2004, knowledge for growth brings over 1300 biotech, pharma, medtech, agricultural and chemical industry experts and decision makers, as well as investors, universities, topnotch research institutes,...
InnoSer welcomes Wim Tiest as its Chief Technology Officer

InnoSer welcomes Wim Tiest as its Chief Technology Officer

As of April 2020, Wim Tiest has joined InnoSer in the role of Chief Technology Officer (CTO) and as part of the company management team. Wim holds a MSc in biochemical engineering and in artificial intelligence, both from the KU Leuven. He has built his professional...